Home > Oncology > ASCO 2020 > Lung Cancer > Second-line gemcitabine plus ramucirumab significantly improves overall survival

Second-line gemcitabine plus ramucirumab significantly improves overall survival

Presented By
Dr Maria Pagano, General Hospital Arcispedale Santa Maria Nuova, Italy
Conference
ASCO20
Trial
Phase 2, RAMES
To date, second-line chemotherapy is not the standard of care in patients with malignant pleural mesothelioma (MPM). The multicenter, double-blind, randomised phase 2 RAMES study explored the efficacy and the safety of the addition of the antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2/KDR) ramucirumab to gemcitabine as the second-line treatment in MPM patients after platinum/pemetrexed regimens. The RAMES study enrolled 161 patients with progressive disease after first-line treatment with platinum/pemetrexed. Patients were randomised to gemcitabine (1,000 mg/m2 IV on days 1 and 8 every 21 days) plus placebo or gemcitabine plus ramucirumab (10 mg/kg IV on day 1, of a 21-day cycle), until tolerability or progressive disease. Median number of courses was 3.50 in the gemcitabine/placebo arm and 7.50 in the gemcitabine/ramucirumab arm. The primary endpoint of the trial was overall survival (OS). Secondary endpoints were ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on